{
  "buildId": "5lGULuFSFhUrfWgBpMJq_",
  "gssp": true,
  "isFallback": false,
  "page": "/calc/[...slug]",
  "props": {
    "__N_SSP": true,
    "pageProps": {
      "calc": {
        "before_use": "",
        "calc_type": "",
        "chief_complaint_en": [
          "Abdominal Pain",
          "Fever",
          "Jaundice"
        ],
        "cmeEndDate": null,
        "cmeLastReviewed": null,
        "cmeReleaseDate": null,
        "cme_status": "",
        "content": {
          "about": {
            "evidence_based_medicine_en": "<p>Guidelines for IRAE in GI toxicity (hepatitis) were developed by a multidisciplinary, multi-organizational panel of experts in medical oncology based on a systematic review of the medical literature.</p>",
            "formula_en": "<div dir=\"ltr\" align=\"left\"><br class=\"Apple-interchange-newline\" />\n<table><colgroup><col width=\"258\" /><col width=\"190\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Hepatitis grade</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Asymptomatic (AST or ALT &gt; ULN to 3.0 x ULN and/or total bilirubin &gt; ULN to 1.5 x ULN)</p>\n</td>\n<td>\n<p dir=\"ltr\">G1</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Asymptomatic (AST or ALT &gt; ULN to 3.0 to 5 x ULN and/or total bilirubin &gt;1.5 to &le;3 x ULN)</p>\n</td>\n<td>\n<p dir=\"ltr\">G2</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Symptomatic liver dysfunction, fibrosis by biopsy, compensated cirrhosis, reactivation of chronic hepatitis (AST or ALT 5-20 x ULN and/or total bilirubin 3-10 x ULN)&nbsp;</p>\n</td>\n<td>\n<p dir=\"ltr\">G3</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Decompensated liver function leg, ascites, coagulopathy, encephalopathy, coma; AST or ALT &gt;20 x ULN and/or total bilirubin &gt;10 x ULN)</p>\n</td>\n<td>\n<p dir=\"ltr\">G4</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">See Next Steps for details on management.</p>",
            "more_info_en": "",
            "references_list": {
              "Clinical Practice Guidelines": [],
              "Manufacturer Website": [],
              "Original/Primary Reference": [
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/29442540 ",
                  "text": "Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768."
                }
              ],
              "Other References": [],
              "Outcomes": [],
              "Validation": []
            }
          },
          "contributor": {
            "expert_name": [
              "Nazli Dizman, MD"
            ]
          },
          "creator": [
            {
              "approved": false,
              "name": "Dr. Julie R. Brahmer",
              "qa_en": ""
            }
          ],
          "how_to_use": {
            "pearls_pitfalls_en": "<ul>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Immune checkpoint inhibitor (ICPi) hepatitis should be suspected in patients with symptoms of hepatitis (i.e., jaundice, severe nausea or vomiting, pain on the right side of the abdomen, drowsiness, dark (tea-colored) urine, easy bleeding or bruising, anorexia) while on treatment with immune checkpoint inhibitors.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">May occur any time during immune checkpoint inhibitor treatment, but most frequently seen 6-12 weeks following treatment initiation.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">More frequently seen with anti-CTLA-4 agents, but is also an important adverse event caused by anti-PD-1 and anti-PD-L1 agents.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Management of immune checkpoint inhibitor hepatitis is based on the grade of hepatitis.</p>\n</li>\n</ul>",
            "use_case_en": "<p>Adult patients with hepatitis symptoms or AST, ALT, or total bilirubin elevation, while on treatment with immune checkpoint inhibitors including agents against PD-1 (i.e. pembrolizumab, nivolumab), PD-L1 (i.e. atezolizumab, avelumab, durvalumab), or CTLA-4 (i.e. ipilimumab).</p>",
            "why_use_en": "<p>ICPi hepatitis is the third most common cause of hospital admissions due to immune related adverse events. This tool aids in the decision of immune checkpoint inhibitor discontinuation, further diagnostic work-up, and immunosuppressant treatment initiation.</p>"
          },
          "next_steps": {
            "advice_en": "<p>Monitor patients for abnormal liver blood tests: AST, ALT, and bilirubin prior to each infusion.&nbsp;</p>\n<p><strong>Grade 1:&nbsp;</strong>Monitor patient for abnormal liver blood tests: AST, ALT, and bilirubin once or twice weekly.</p>\n<p><strong>Grade 2-4:&nbsp;</strong>Further diagnostic work-up is recommended as following:&nbsp;</p>\n<ul>\n<li>Work-up for other causes of elevated liver enzymes, including viral hepatitis, alcohol history, iron studies, thromboembolic event, liver ultrasound, cross-sectional imaging for potential liver metastasis from primary malignancy. Consider antinuclear antibodies, antismooth muscle antibodies, antineutrophil cytoplasmic antibodies if suspicion for primary autoimmune hepatitis is high.</li>\n<li>Work-up for other etiologies: consider checking creatine kinase for isolated elevation of transaminases.</li>\n</ul>",
            "critical_actions_en": "<p>Infliximab, as an immunosuppressant, might not be the most appropriate treatment option due to potential risk of liver failure despite no clinical evidence in the literature; alternatives include non&ndash;TNF-&alpha; agents as systemic immunosuppressants.</p>",
            "management_en": "<p dir=\"ltr\">For all patients where an IRAE diagnosis is being considered, it is always recommended to involve the specialist or team prescribing the immune checkpoint therapy.</p>\n<p dir=\"ltr\"><strong>All patients</strong></p>\n<ul>\n<li dir=\"ltr\">Counsel all patients to be aware of and inform their health care provider immediately if they experience any of the following:\n<ul>\n<li dir=\"ltr\">Yellowing of skin or whites of the eyes, severe nausea or vomiting, pain on the right side of the abdomen, drowsiness, dark urine (tea colored), bleeding or bruising more easily than normal, feeling less hungry than usual.</li>\n</ul>\n</li>\n</ul>\n<p dir=\"ltr\"><strong>Grade 1:</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Continue immune checkpoint inhibitor with close monitoring.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider alternate etiologies.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Monitor laboratories one to two times weekly.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Manage with supportive care for symptom control.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 2:&nbsp;</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Hold immune checkpoint inhibitor temporarily and resume if recovers to grade 1 or less on prednisone &le; 10 mg/d.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">For patients with symptoms, consider corticosteroid 0.5&ndash;1 mg/kg/d prednisone or equivalent if the abnormal elevation persists with significant clinical symptoms in 3&ndash;5 days.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Increase frequency of monitoring to every 3 days.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Infliximab might not be the most appropriate treatment option in the situation of immune-mediated hepatitis given the potential risk of idiosyncratic liver failure (Note: No clear evidence shows the liver toxicity from infliximab from other studies).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">In follow-up, may resume immune checkpoint inhibitor treatment followed by taper only when symptoms improve to G1 or less and corticosteroid &le; 10 mg/d; taper over at least 1 month.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Patients should be advised to stop unnecessary medications and any known hepatotoxic drugs.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 3:&nbsp;</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Often corticosteroid 1&ndash;2 mg/kg methylprednisolone or equivalent is recommended.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If corticosteroid refractory or no improvement after 3 days, consider mycophenolate mofetil or azathioprine (if using azathioprine should test for thiopurine methyltransferase deficiency).</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Laboratories at daily or every other day; consider inpatient monitoring for patients with AST/ALT &gt; 8 &times; ULN and/or elevated TB 3 &times; ULN Increase frequency of monitoring to every 1&ndash;2 days.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Infliximab might not be the most appropriate treatment option in the situation of immune-mediated hepatitis given the potential risk of liver failure (Note: No clear evidence shows that the liver toxicity from infliximab from other studies); alternatives include non&ndash;TNF-&alpha; agents as systemic immunosuppressants.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Corticosteroid taper can be attempted around 4&ndash;6 weeks; re-escalate if needed; optimal duration unclear.</p>\n</li>\n</ol>\n<p dir=\"ltr\"><strong>Grade 4:&nbsp;</strong></p>\n<ol>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Permanently discontinue immune checkpoint inhibitor.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Steroid 2 mg/kg/d methylprednisolone equivalents should be considered.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">If corticosteroid refractory or no improvement after 3 days, consider mycophenolate mofetil.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Monitor laboratories daily; consider inpatient monitoring.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Avoid the use of infliximab in the situation of immune-mediated hepatitis.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consult hepatology if no improvement was achieved with corticosteroid.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Corticosteroid taper can be attempted around 4&ndash;6 weeks when symptoms improve to G1 or less; re-escalate if needed; optimal duration unclear.</p>\n</li>\n<li dir=\"ltr\" aria-level=\"1\">\n<p dir=\"ltr\" role=\"presentation\">Consider transfer to tertiary care facility if necessary.</p>\n</li>\n</ol>\n<p><span id=\"docs-internal-guid-d3c7f420-7fff-1ee8-32d7-dd2494c14bb4\">See&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29442540\" target=\"_blank\" rel=\"noopener\">Brahmer 2018</a>&nbsp;for full ASCO guidelines.</p>"
          },
          "related_resources": {
            "guidelines": [],
            "interests": [],
            "mdcalc_rating": [],
            "partner_contact": [],
            "sdm_tool": [],
            "teaching": [],
            "videos": []
          },
          "reviewer": []
        },
        "disease_en": [
          "Hepatitis"
        ],
        "dosing": false,
        "equation_logic_text": "var calc_output = [];\n\nvar grading = parseFloat(grading);\nvar rec;\n\nswitch (grading) {\n  case 1:\n    rec = 'Continue ICPi with close monitoring; consider alternate etiologies; labs 1-2 times weekly; supportive care for symptoms; see Next Steps for details';\n    break;\n  case 2:\n    rec = 'Hold ICPi temporarily; consider prednisone ≤10 mg/d; consider resuming ICPi if pt recovers to Grade 1; consider d/c other hepatotoxic meds; if symptomatic and persistent consider 0.5–1 mg/kg/d prednisone or equivalent; monitor every 3 days; see Next Steps for details';\n    break;\n  case 3:\n    rec = 'Immediately start 1-2 mg/kg methylprednisone or equivalent; if refractory/unresponsive consider MMF or azathioprine; monitor daily or every other day; consider admission if AST/ALT >8 x ULN and/or elevated TB 3 x ULN; consider immunosuppressants; see Next Steps for details';\n    break;\n  case 4:\n    rec = 'Permanently d/c ICPi; start 2 mg/kg/d methylprednisolone equivalent; consider admission; monitor daily; if refractory/unresponsive consider MMF, consult hepatology; avoid infliximab; Consider transfer to tertiary care facility; see Next Steps for details';\n}\n\n//results\ncalc_output.push({\n    name: 'mini',\n    value: 'G'+grading,\n    value_text: '',\n    message: 'Hepatitis grade'   \n});\ncalc_output.push({\n    name: 'Score',\n    value: 'G'+grading,\n    value_text: '',\n    message: 'Hepatitis grade'   \n});\ncalc_output.push({\n    name: 'risk1',\n    value: '', \n    value_text: '',\n    message: rec\n});",
        "favorite_id": 10389,
        "full_title_en": "Immune-Related Adverse Events for GI Toxicity - Hepatitis",
        "input_schema": [
          {
            "conditionality": "",
            "default": null,
            "label_en": "Criteria",
            "name": "grading",
            "optional": false,
            "options": [
              {
                "label": "Asymptomatic (AST or ALT > ULN to 3.0 x ULN and/or total bilirubin > ULN to 1.5 x ULN)",
                "value": 1
              },
              {
                "label": "Asymptomatic (AST or ALT > ULN to 3.0 to 5 x ULN and/or total bilirubin >1.5 to ≤3 x ULN)",
                "value": 2
              },
              {
                "label": "Symptomatic liver dysfunction, fibrosis by biopsy, compensated cirrhosis, reactivation of chronic hepatitis (AST or ALT 5-20 x ULN and/or total bilirubin 3-10 x ULN)",
                "value": 3
              },
              {
                "label": "Decompensated liver function leg, ascites, coagulopathy, encephalopathy, coma; AST or ALT >20 x ULN and/or total bilirubin >10 x ULN)",
                "value": 4
              }
            ],
            "show_points": false,
            "tips_en": "",
            "type": "radio"
          }
        ],
        "instructions_en": "<p>Use in adult patients with symptoms of hepatitis or AST, ALT, or total bilirubin elevation that developed while on treatment with immune checkpoint inhibitors.</p>",
        "md5": "",
        "medium_description_en": "<p>Grades severity of hepatitis secondary to immune checkpoint inhibitor therapy.</p>",
        "purpose_en": [
          "Diagnosis",
          "Prognosis"
        ],
        "search_abbreviation_en": [
          "Immune Related Adverse Events, irae, hepatitis, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO"
        ],
        "search_id": "c-10389",
        "seo": {
          "keywords_en": "Immune Related Adverse Events, irae, hepatitis, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO",
          "meta_description_en": "The Immune-Related Adverse Events for GI Toxicity - Hepatitis grades severity of hepatitis secondary to immune checkpoint inhibitor therapy."
        },
        "short_description_en": "Grades severity of hepatitis secondary to immune checkpoint inhibitor therapy.",
        "short_title_en": "IRAE for GI Toxicity - Hepatitis",
        "slug": "immune-related-adverse-events-gi-toxicity-hepatitis",
        "specialty_en": [
          "Allergy and Immunology",
          "Gastroenterology",
          "Hepatology",
          "Hospitalist Medicine",
          "Internal Medicine"
        ],
        "system_en": [
          "Gastrointestinal",
          "Hepatic"
        ]
      },
      "contributors": [
        {
          "contributors_page": false,
          "description": "",
          "firstName": "Nazli",
          "hasDisclosure": [],
          "img": "",
          "lastName": "Dizman",
          "name": "Nazli Dizman, MD",
          "signedCOI": true,
          "status": "",
          "target": ""
        }
      ],
      "creators": [
        {
          "about_en": "<p>Julie R. Brahmer, MSc, MD, is the co-director of the upper aerodigestive department at Johns Hopkins Medicine in Baltimore, MD. She is also a professor of oncology at Johns Hopkins Medicine. Dr. Brahmer’s primary research is focused on treatment of lung cancer and mesothelioma.</p>",
          "deceased": false,
          "description": "",
          "firstName": "",
          "img": "",
          "lastName": "",
          "name": "Dr. Julie R. Brahmer",
          "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-julie-brahmer.png",
          "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Brahmer+JR%5BAuthor%5D",
          "signedCOI": false
        }
      ],
      "envs": {
        "CANONICAL_URL_ROOT": "https://www.mdcalc.com",
        "CONTENT_SERVER_TAG": "WEB_PROD",
        "RECAPTCHA_PUBLIC_KEY": "6Lcu1mMkAAAAAAwmSDO3I7JNaUo9YtZ3jnrzTP6a",
        "STRIPE_PUB_KEY": "pk_live_yYm2UzDzaudhFgqWcKbv9vH7"
      },
      "faqs": [
        {
          "cme_faq": {
            "answer": "<p>MDCalc&rsquo;s Continuing Medical Education (CME) service allows users to easily earn AMA PRA Category 1 CreditsTM through regular use of MDCalc. Simply put, on top of getting the best medical calculators in the world, your usage will help you achieve your annual CME requirements, including specialty CME, without any extra effort.</p>",
            "question": "What is MDCalc CME?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Yes, in support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MDCalc Ltd. Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>",
            "question": "Is MDCalc CME accredited?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Only United States attending physicians, nurse practitioners, nurses, and physician assistants are eligible for our CME service.</p>",
            "question": "Who can enroll and how?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>We have over 275 CME-eligible calculators across various specialties. You can read the clinical content supporting any CME calculators to start earning. Once you have viewed all the supporting content for a calculator, you will have officially earned the credit amount (0.5 credits) and will be able to redeem a certificate. For now, only calc content in CME-eligible calcs is eligible for CME credits, however, we&rsquo;ll be expanding our CME service to include more of our content in the future.</p>",
            "question": "What activities can I do to earn CME credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Simply use our search bar or visit our homepage to easily find CME-eligible calcs. You must be enrolled in our CME service to see which calcs are CME-eligible.</p>",
            "question": "Where can I find calcs with which I can earn credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Once you&rsquo;ve enrolled in our CME service, you will have a personal CME Dashboard where you can view all of your earned credits. You can navigate to the dashboard by clicking the CME button in the header at the top of any page.</p>",
            "question": "Where can I see which credits I’ve earned?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Go to your CME Dashboard and select the credits you&rsquo;d like to redeem, fill out a few dropdown answers about how you used the calc, and then proceed to checkout.</p>",
            "question": "How do I redeem CME credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>No. Earning credits as you use calcs is free, but either you (or your employer) will need to purchase an annual subscription to redeem your CME certificates.</p>",
            "question": "Are CME credits free?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Just like with earned credits, you can view your CME certificates on your CME Dashboard in the &ldquo;CME Certificates&rdquo; tab. Certificates include a list of all of the calcs for which CME was earned along with a tally of the specialty CME.</p>",
            "question": "Where can I see my CME certificates?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>One year from the date of purchase.</p>",
            "question": "How long do credits in an annual subscription last?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>General; Addiction and Controlled Substances; Cardiac Care; Domestic and Intimate Partner Violence; Geriatrics; HIV and Infectious Disease; Hospice, End-of-Life, Terminal Illness, and Palliative Care; Mental and Behavioral Health; Pain Management; Pediatrics; Stroke; and Trauma.</p>",
            "question": "What specialty CME credits are included in the plan?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Your gift card will be sent via email within 1-2 business days of making your purchase. You will be able to select from the following options - Visa, Amazon.com, Apple. Be sure to claim your gift card offer within 90 days of receiving the email.</p>\n<p>Your CME purchase may have implications for tax reporting purposes. The cost of your CME product may or may not be tax-deductible when used for professional purposes. Any reimbursed amount for incentives must be declared as personal income for tax purposes. Please consult your tax advisor. MDCalc does not provide tax advice.</p>",
            "question": "I ordered a CME package with a gift card. How does it work?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Per the new guidelines from ACCME, the receipt will separate the cost you paid into the cost of the gift card and the cost of the CME learning activity.</p>",
            "question": "What will show on my receipt for CME when it includes a gift card?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>You can get a refund (minus any promotional gift amount) within 30-days if the ease of earning and redeeming does not meet your expectations and if you have redeemed no more than 4 credits. Please email <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> to request a refund.</p>",
            "question": "How do I get a refund if I'm not satisfied?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>You can upgrade your subscription throughout your billing cycle and pay the difference for a higher plan. You may request to downgrade your plan to a lower level to coincide with your next renewal. Please email <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> to request changes.</p>",
            "question": "How do I later upgrade to a different plan if I need more credits?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Gift card plans are available for 1 year and do not auto-renew. Standard, non gift-card subscriptions are auto-renewed annually. You can disable the automatic renewal of your subscription at any time by emailing <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a>.</p>",
            "question": "Do CME plans auto-renew?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>If you&rsquo;re part of a team or practice that wants to sign up five or more physicians, please email us at <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> for more information.</p>",
            "question": "How do I get information on a discounted bulk subscription program for my institution, team, or practice?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>On July 28, 2022, ACCME updated the guidelines regarding the use of high-value incentives. These guidelines allow for the use of gift card rewards in a regulated manner. Visit the ACCME website to read their guidelines.</p>",
            "question": "Did the ACCME decide to regulate gift cards?",
            "type": "Purchasing"
          }
        }
      ],
      "headConfig": {
        "canonicalUrl": "/calc/10389/immune-related-adverse-events-gi-toxicity-hepatitis",
        "description": "The Immune-Related Adverse Events for GI Toxicity - Hepatitis grades severity of hepatitis secondary to immune checkpoint inhibitor therapy.",
        "keywords": "Immune Related Adverse Events, irae, hepatitis, immune checkpoint inhibitor therapy, ICPi therapy, ASCO guideline, ASCO",
        "title": "Immune-Related Adverse Events for GI Toxicity - Hepatitis"
      },
      "isCMECalc": false,
      "measurements": [],
      "relCalcs": [
        {
          "calcId": 10378,
          "short_title_en": "IRAE for Renal Toxicities - Nephritis",
          "slug": "immune-related-adverse-events-renal-toxicities-nephritis"
        },
        {
          "calcId": 10383,
          "short_title_en": "IRAE for Lung Toxicity - Pneumonitis",
          "slug": "immune-related-adverse-events-lung-toxicity-pneumonitis"
        },
        {
          "calcId": 10377,
          "short_title_en": "IRAE for Endocrine Toxicities - Diabetes",
          "slug": "immune-related-adverse-events-endocrine-toxicities-diabetes-mellitus"
        }
      ],
      "societies": {
        "American Association for the Study of Liver Diseases": {
          "abbreviation": "AASLD",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.aasld.org/"
        },
        "American College Of Emergency Physicians": {
          "abbreviation": "ACEP",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/apps.mdcalc.com/images/american-college-of-emergency-physicians-squarelogo.png",
          "web_link": "https://www.acep.org/"
        },
        "American College of Gastroenterology": {
          "abbreviation": "ACG",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/acg_logo.png",
          "web_link": "https://gi.org/"
        },
        "American College of Rheumatology": {
          "abbreviation": "ACR",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.rheumatology.org/"
        },
        "American Gastroenterological Association": {
          "abbreviation": "AGA",
          "description": "plain-text",
          "img": "https://apps.mdcalc.com/images/societies/aga.jpeg",
          "web_link": "https://gastro.org"
        },
        "American Heart Association": {
          "abbreviation": "AHA",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/apps.mdcalc.com/images/societies/+AHA+(American+Heart+Association).png",
          "target": "aha",
          "web_link": "http://www.heart.org/HEARTORG/"
        },
        "American Urological Association": {
          "abbreviation": "AUA",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.auanet.org/"
        },
        "EB Medicine": {
          "abbreviation": "EB Medicine",
          "description": "EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.",
          "img": "https://cdn-web-img.mdcalc.com/other/eb_medicine-icon-only.jpg",
          "target": "eb-medicine",
          "web_link": "http://www.ebmedicine.net/"
        },
        "MDCalc CME": {
          "abbreviation": "MDCalc CME",
          "img": "https://cdn-web-img.mdcalc.com/Stroke-CME-content.jpg",
          "web_link": "https://www.mdcalc.com/stroke-cme?utm_source=NIHSS_calc&utm_medium=NIHSS_calc&utm_campaign=NIHSS_calc"
        },
        "OTHER": {
          "abbreviation": "OTHER"
        },
        "Postgraduate Institute for Medicine": {
          "abbreviation": "PIM",
          "description": "plain-text",
          "img": "https://cdn-web-img.mdcalc.com/PIM-circle-COLOR.jpeg",
          "target": "pim",
          "web_link": "https://www.pimed.com/"
        },
        "VACO Podcast": {
          "description": "Listen to the VACO co-creators break down how to use VACO\\, what it does\\, and what it doesn’t.",
          "img": "https://cdn-web-img.mdcalc.com/content/podcast 2.png",
          "web_link": "https://www.stimuluspodcast.com/post/32-the-covid-mortality-score-vaco"
        }
      },
      "validSections": [
        "whenToUseViewed",
        "pearlsPitfallsViewed",
        "whyUseViewed",
        "nextStepsViewed",
        "evidenceViewed"
      ]
    }
  },
  "query": {
    "slug": [
      "10389",
      "immune-related-adverse-events-gi-toxicity-hepatitis"
    ]
  },
  "scriptLoader": []
}